肝硬化或肝衰竭等待肝移植患者中丙型肝炎病毒感染、非酒精性脂肪性肝炎和酒精性肝病患病率的变化
该研究通过分析美国国家健康与营养调查、HealthCore数据库和器官共享联合网络三个数据库,评估肝硬化或肝衰竭等待肝移植患者中丙型肝炎病毒(HCV)、非酒精性脂肪性肝炎(NASH)和酒精性肝病(ALD)患病率的变化。结果显示,HCV相关肝硬化或肝衰竭比例下降,而NASH和ALD比例上升,但肝细胞癌(HCC)患者中HCV、NASH或ALD比例在2003至2015年间无变化。
要点
- 2013-2014年HCV抗体阳性者中HCV RNA阳性比例为0.5,显著低于2010年的0.64(P=0.03)。
- HealthCore数据库中,代偿性肝硬化、慢性肝衰竭(CLF)和HCC患者中HCV或ALD比例下降,NASH比例上升,CLF中NASH比例近乎增加3倍。
- 器官共享联合网络数据显示,因CLF新进入等待名单或接受移植者中HCV比例显著下降,非酒精性脂肪性肝病或ALD比例上升;因HCC者中HCV、NASH或ALD比例无变化。
核心结论
- 在三个数据库分析中,因慢性HCV感染等待肝移植或接受肝移植的患者比例下降,肝硬化或CLF患者减少;但因NASH或ALD等待或接受肝移植的比例上升,尽管全肝硬化人群中疾病相对负担不同。
研究设计与样本
- 研究收集2010年和2013-2014年国家健康与营养调查中HCV患病率数据,HealthCore综合研究数据库中2006至2014年肝硬化或慢性肝衰竭患者数据,以及器官共享联合网络中2003至2015年接受移植患者数据。
- 采用Spearman秩相关、非参数趋势检验和线性回归模型,将每个日历年作为连续变量建模,确定新等待名单成员和移植受者中HCV感染百分比,并按移植指征分层。
主要发现
- 国家健康与营养调查(2013-2014)分析显示,HCV抗体阳性患者中HCV RNA阳性比例为0.5(95%CI 0.42-0.55),显著低于2010年的0.64(95%CI 0.59-0.73)(P=0.03)。
- HealthCore数据库显示,随时间变化,代偿性肝硬化患者中HCV或ALD所致肝硬化百分比下降,NASH所致肝硬化百分比上升;CLF患者中HCV或ALD所致CLF百分比下降,NASH所致CLF百分比近乎增加3倍;HCC患者中HCV或ALD所致HCC百分比下降,NASH人群HCC小幅增加(所有P<0.05)。
- 器官共享联合网络数据显示,因CLF新进入肝移植等待名单或接受肝移植的患者中,HCV感染百分比显著下降,非酒精性脂肪性肝病或ALD百分比上升;因HCC新进入等待名单或接受肝移植的患者中,HCV感染、非酒精性脂肪性肝病或ALD比例在2003至2015年间无变化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Concurrent to development of more effective drugs for treatment of hepatitis C virus (HCV) infection, there has been an increase in the incidence of nonalcoholic fatty liver disease. Data indicate that liver transplantation prolongs survival times of patient with acute hepatitis associated with alcoholic liver disease (ALD). We compared data on disease prevalence in the population with data from liver transplantation waitlists to evaluate changes in the burden of liver disease in the United States. METHODS: We collected data on the prevalence of HCV from the 2010 and 2013-2014 cycles of the National Health and Nutrition Examination Survey. We also collected data from the HealthCore Integrated Research Database on patients with cirrhosis and chronic liver failure (CLF) from 2006 through 2014, and data on patients who received transplants from the United Network for Organ Sharing from 2003 through 2015. We determined percentages of new waitlist members and transplant recipients with HCV infection, stratified by indication for transplantation, modeling each calendar year as a continuous variable using the Spearman rank correlation, nonparametric test of trends, and linear regression models. RESULTS: In an analysis of data from the National Health and Nutrition Examination Survey (2013-2014), we found that the proportion of patients with a positive HCV antibody who had a positive HCV RNA was 0.5 (95% confidence interval, 0.42-0.55); this value was significantly lower than in 2010 (0.64; 95% confidence interval, 0.59-0.73) (P = .03). Data from the HealthCore database revealed significant changes (P < .05 for all) over time in percentages of patients with compensated cirrhosis (decreases in percentages of patients with cirrhosis from HCV or ALD, but increase in percentages of patients with cirrhosis from nonalcoholic steatohepatitis [NASH]), CLF (decreases in percentages of patients with CLF from HCV or ALD, with an almost 3-fold increase in percentage of patients with CLF from NASH), and hepatocellular carcinoma (HCC) (decreases in percentages of patients with HCC from HCV or ALD and a small increase in HCC among persons with NASH). Data from the United Network for Organ Sharing revealed that among patients new to the liver transplant waitlist, or undergoing liver transplantation, for CLF, there was a significant decrease in the percentage with HCV infection and increases in percentages of patients with nonalcoholic fatty liver disease or ALD. Among patients new to the liver transplant waitlist or undergoing liver transplantation for HCC, proportions of those with HCV infection, nonalcoholic fatty liver disease, or ALD did not change between 2003 and 2015. CONCLUSIONS: In an analysis of 3 different databases (National Health and Nutrition Examination Survey, HealthCore, and United Network for Organ Sharing), we found the proportion of patients on the liver transplant waitlist or undergoing liver transplantation for chronic HCV infection to be decreasing and fewer patients to have cirrhosis or CLF. However, the percentages of patients on the waitlist or receiving liver transplants for NASH or ALD are increasing, despite different relative burdens of disease among the entire population of patients with cirrhosis.
引用
- Goldberg D, Ditah IC, Saeian K, et al. Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. Gastroenterology. 2017. PMID: 28088461. doi:10.1053/j.gastro.2017.01.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。